Viatris
VTRS
17.49
-0.05
-0.29%
Viatris
US · VTRS
#916 by market cap
Listed 1970
17.49
-0.05
-0.29%
Live - 5344 symbols - heartbeat 448s ago
· 2026-10-08 07:40
Pre-market
17.49
0.00%
After-hours
17.51
+0.11%
Overnight
17.60
+0.63%
- Market cap
- 20.09B
- P/E (TTM)i
- -47.27
- P/Bi
- 1.41
- EPSi
- -3.00
- Div yieldi
- 2.74%
- 52W posi
- 90%
Reader sentiment
Are you bullish or bearish on VTRS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.02, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -2.98% YoY
Margins
- Gross margin
- 35.06%
- Operating margin
- 1.77%
- Net margin
- -24.58%
Key ratios & quality
- Enterprise valuei
- 33.10B
- Altman Z-Scorei
- 1.02
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.43B | 11.50B | 11.95B | 17.89B | 16.26B | 15.43B | 14.74B | 14.30B |
| Gross profit | 4.00B | 3.90B | 3.80B | 5.58B | 6.50B | 6.44B | 5.62B | 5.01B |
| Selling & admin expenses | 2.44B | 2.56B | 3.34B | 4.53B | 4.18B | 4.07B | 4.10B | 3.79B |
| Research & development | 704.50M | 639.90M | 512.60M | 681.00M | 662.20M | 805.20M | 808.70M | 965.90M |
| Operating profit | 856.10M | 694.10M | -60.50M | 365.30M | 1.66B | 1.56B | 710.30M | 253.50M |
| Pretax profit | 298.40M | 154.40M | -721.20M | -664.40M | 2.81B | 202.90M | -623.20M | -3.67B |
| Tax | -54.10M | 137.60M | -51.30M | 604.70M | 734.60M | 148.20M | 11.00M | -150.10M |
| Net profit | 352.50M | 16.80M | -669.90M | -1.27B | 2.08B | 54.70M | -634.20M | -3.51B |
| Basic EPS | 1 | 0 | -1 | -1 | 2 | 0 | -1 | -3 |
| Diluted EPS | 0.68 | 0.03 | -1.11 | -1.05 | 1.71 | 0.05 | -0.53 | -3.00 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 3.25B | 3.58B | 3.76B | 3.70B | 3.52B | 3.76B |
| Gross profit | 1.16B | 1.33B | 1.37B | 1.15B | 1.16B | 1.46B |
| Selling & admin expenses | 948.10M | 928.70M | 886.60M | 1.03B | 928.80M | 1.13B |
| Research & development | 222.00M | 218.80M | 250.40M | 274.70M | 248.60M | 248.30M |
| Operating profit | -8.90M | 185.40M | 234.50M | -157.50M | -20.20M | 73.70M |
| Pretax profit | -3.10B | -217.10M | -7.90M | -343.00M | -247.30M | -64.00M |
| Tax | -55.00M | -212.50M | 120.30M | -2.90M | -423.70M | 54.80M |
| Net profit | -3.04B | -4.60M | -128.20M | -340.10M | 176.40M | -118.80M |
| Basic EPS | -3 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -2.55 | 0.00 | -0.11 | -0.30 | 0.15 | -0.10 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 6.37B | 6.76B | 12.87B | 10.90B | 10.64B | 12.98B | 9.52B | 9.79B |
| Cash & ST investments | 479.40M | 584.70M | 1.05B | 935.00M | 1.47B | 1.18B | 1.09B | 1.51B |
| Inventory | 2.58B | 2.67B | 5.47B | 3.98B | 3.52B | 3.47B | 3.85B | 4.00B |
| Total assets | 32.73B | 31.26B | 61.55B | 54.84B | 50.02B | 47.69B | 41.50B | 37.19B |
| Total current liabilities | 4.59B | 5.57B | 10.56B | 9.88B | 6.75B | 7.78B | 5.78B | 7.09B |
| Short-term debt | 701.70M | 1.53B | 3.50B | 3.44B | 1.33B | 2.02B | 87.70M | 2.04B |
| Long-term debt | 13.16B | 11.21B | 22.43B | 19.72B | 18.02B | 16.19B | 14.04B | 12.48B |
| Total liabilities | 20,567,800,000.00 | 19,371,700,000.00 | 38,598,900,000.00 | 34,350,100,000.00 | 28,949,900,000.00 | 27,218,100,000.00 | 22,865,400,000.00 | 22,481,800,000.00 |
| Total equity | 12.17B | 11.88B | 22.95B | 20.49B | 21.07B | 20.47B | 18.64B | 14.71B |
| Retained earnings | 6.01B | 6.03B | 5.36B | 3.69B | 5.18B | 4.64B | 3.42B | -388.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 9.62B | 9.77B | 9.95B | 9.79B | 10.92B | 10.06B |
| Cash & ST investments | 1.00B | 808.60M | 1.16B | 1.51B | 2.40B | 1.51B |
| Inventory | 4.10B | 4.26B | 4.11B | 4.00B | 3.93B | 3.93B |
| Total assets | 38.47B | 38.41B | 37.92B | 37.19B | 36.83B | 35.04B |
| Total current liabilities | 5.72B | 7.13B | 7.36B | 7.09B | 6.81B | 6.35B |
| Short-term debt | 103.90M | 1.78B | 2.06B | 2.04B | 2.03B | 1.85B |
| Long-term debt | 14.18B | 12.79B | 12.49B | 12.48B | 12.41B | 11.61B |
| Total liabilities | 22,824,500,000.00 | 22,841,000,000.00 | 22,702,800,000.00 | 22,481,800,000.00 | 22,176,900,000.00 | 20,784,200,000.00 |
| Total equity | 15.65B | 15.57B | 15.22B | 14.71B | 14.66B | 14.26B |
| Retained earnings | 227.90M | 80.00M | -48.20M | -388.30M | -211.90M | -330.70M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2.34B | 1.80B | 1.23B | 3.02B | 3.00B | 2.90B | 2.30B | 2.32B |
| Depreciation & amortization | 2.11B | 2.02B | 2.22B | 4.51B | 3.03B | 2.74B | 2.89B | 2.80B |
| Free cash flow | 1.15B | 1.40B | 550.60M | 2.51B | 2.51B | 2.33B | 1.94B | 1.85B |
| Dividends paid | -- | 0 | 0 | -399.00M | -581.60M | -575.60M | -574.80M | -561.20M |
| Stock buybacks / issuance | -432.00M | -- | 0 | 0 | 3.30M | -246.90M | -247.50M | -497.90M |
| Ending cash balance | 389.30M | 491.10M | 850.00M | 706.20M | 1.26B | 993.60M | 736.10M | 1.35B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 535.50M | 219.70M | 744.90M | 815.80M | 388.30M | 381.80M |
| Depreciation & amortization | 664.70M | 678.30M | 688.50M | 766.80M | 676.10M | 672.30M |
| Free cash flow | 459.10M | 165.60M | 645.20M | 580.90M | 264.10M | 322.00M |
| Dividends paid | -143.30M | -139.80M | -139.90M | -138.20M | -139.60M | -139.80M |
| Stock buybacks / issuance | -174.80M | -174.30M | -64.30M | -84.50M | 500.00K | -149.30M |
| Ending cash balance | 756.30M | 567.80M | 1.00B | 1.35B | 1.81B | 890.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 2.77 | 0.14 | -3.85 | -5.84 | 10.00 | 0.26 | -3.24 | -21.08 |
| ROA %i | 1.03 | 0.05 | -1.44 | -2.18 | 3.96 | 0.11 | -1.42 | -8.93 |
| ROIC %i | 2.77 | 1.55 | -0.56 | -1.73 | 5.96 | 1.28 | -0.56 | -9.82 |
| 5-year avg ROE %i | 11.22 | 5.24 | 1.87 | -0.22 | 0.64 | 0.14 | -0.53 | -3.98 |
| EBIT margin %i | 7.35 | 5.84 | -1.87 | -0.16 | 20.94 | 5.03 | -0.50 | -22.33 |
| FCF / sales %i | 10.02 | 12.15 | 4.61 | 14.02 | 15.43 | 15.07 | 13.19 | 12.94 |
| Current ratioi | 1.39 | 1.21 | 1.22 | 1.10 | 1.58 | 1.67 | 1.65 | 1.38 |
| Quick ratioi | 0.73 | 0.65 | 0.56 | 0.53 | 0.83 | 0.67 | 0.80 | 0.69 |
| Debt / assetsi | 42.35 | 41.35 | 42.50 | 42.59 | 39.04 | 38.53 | 34.47 | 39.52 |
| LT debt / equityi | 108.17 | 95.84 | 98.71 | 97.20 | 86.35 | 79.90 | 76.30 | 86.05 |
| Interest coveragei | 1.55 | 1.30 | -0.45 | -0.04 | 5.75 | 1.35 | -0.13 | -6.78 |
| Revenue CAGR (3Y) %i | 6.64 | 1.26 | 0.11 | 16.08 | 12.24 | 8.90 | -6.25 | -4.20 |
| Net income CAGR (3Y) %i | -25.36 | -67.29 | -- | -- | 398.30 | -- | -- | -- |
| FCF CAGR (3Y) %i | 0.20 | 2.53 | -22.19 | 29.82 | 21.54 | 61.63 | -8.14 | -9.65 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -21.25 | -19.77 | -21.09 | -21.08 | -1.96 | -2.75 |
| ROA %i | -8.83 | -8.28 | -8.93 | -8.93 | -0.79 | -1.12 |
| ROIC %i | -9.60 | -8.95 | -9.85 | -9.82 | -0.04 | -0.39 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -23.71 | -23.04 | -23.91 | -22.33 | -2.33 | -1.24 |
| FCF / sales %i | 12.83 | 12.01 | 11.32 | 12.94 | 11.37 | 12.30 |
| Current ratioi | 1.68 | 1.37 | 1.35 | 1.38 | 1.60 | 1.58 |
| Quick ratioi | 0.77 | 0.62 | 0.64 | 0.69 | 0.90 | 0.82 |
| Debt / assetsi | 37.58 | 38.42 | 38.81 | 39.52 | 39.66 | 38.88 |
| LT debt / equityi | 91.72 | 83.32 | 83.19 | 86.05 | 85.83 | 82.55 |
| Interest coveragei | -6.45 | -6.53 | -7.16 | -6.78 | -0.71 | -0.38 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Brands is the largest reported line at 64.37% of revenue, across 3 reported segments.
- Generics follows at 35.34%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Brands64.37%
Generics35.34%
Other revenues0.29%
Quote time 2026-10-08 07:40:17 · For reference only, not investment advice and not tailored to your situation.